This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate the effects B-cell depletion with Rituximab (a monoclonal antibody against the CD20 antigen on B-lymphocytes) on serum HCV RNA in patients with clinically symptomatic mixed ceyoglobulinemia and chronic HCV liver disease. Our planned studies will compare HCV clearance from serum in two groups of patients, with and without rituximab. This study will help to determine the role of B-cells in HCV clearnce. We will investigate whethr changes in the titers of neutralizing antibodies (nAbs), associated with B cell depletion correlate with the increase in HCV RNA after rituximab. Changes in IgG and IgM anti-E1 E2 antibody responses will also be correlated. This will help us to determine the potential role of nAbs and of anti-E1 E2 antibodies produced by B-cells in the control of HCV load.
Showing the most recent 10 out of 370 publications